A team of investigators conducted a double-blind, placebo-controlled, phase 3 trial to assess outcomes following olaparib treatment in patients with BRCA 1/2-mutated, relapsed ovarian cancer.
The number of genes tested for ovarian and breast cancer has grown, but most patients do not undergo testing, and variant-of-unknown-significance results are common, especially among minority populations.
Investigators of the observational study sought to clarify the time-dependent effects between long-term oral contraceptive use and risk for breast, ovarian, and endometrial cancer risk.
Use of neoadjuvant chemotherapy for patients with stage IIIC and IV epithelial ovarian cancer has increased from 2004 to 2016.
Hyperthermic intraperitoneal chemotherapy added to cytoreductive surgery improved outcomes compared with surgery alone in a cohort study.
Researchers identified factors for increased risk of clinically significant fatigue among women who underwent surgery for gynecologic cancers.
Broad use of PARP inhibitors to treat advanced-stage ovarian cancer would be associated with high costs compared with their biomarker-directed use.
Quality-adjusted progression-free survival (QA-PFS) represents an adjustment to PFS that incorporates patient-reported toxicity and other detrimental effects of treatment.
Patients with low-grade serous carcinoma of the ovary or peritoneum (LGSC) developed chemoresistance to neoadjuvant platinum-based therapy.
Study results differ from prior research into microRNAs as predictive biomarkers.
